These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23457895)

  • 1. A case of treating cathinone dependence and comorbid depression using bupropion.
    Lev-Ran S
    J Psychoactive Drugs; 2012; 44(5):434-6. PubMed ID: 23457895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Successful treatment of depression in a Parkinson disease patient with bupropion].
    Leentjens AF; Verhey FR; Vreeling FW
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2157-9. PubMed ID: 11086491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults.
    Castaneda R; Levy R; Hardy M; Trujillo M
    Psychiatr Serv; 2000 Feb; 51(2):169-71. PubMed ID: 10654994
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of bupropion in the treatment of pemoline dependence.
    Martín Morgado B; Vaz Leal FJ; Bolívar Perálvarez M; Guisado Macías JA
    Actas Esp Psiquiatr; 2007; 35(4):277-8. PubMed ID: 17592792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo.
    Levin FR; Evans SM; Brooks DJ; Kalbag AS; Garawi F; Nunes EV
    Drug Alcohol Depend; 2006 Feb; 81(2):137-48. PubMed ID: 16102908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Beta-cathinone derivatives--a new generation of dangerous psychostimulant "designer drugs"].
    Zawilska JB; Słomiak K; Wasiak M; Woźniak P; Massalski M; Krupa E; Wojcieszak JŁ
    Przegl Lek; 2013; 70(6):386-91. PubMed ID: 24052975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.
    Raskin S; Durst R
    Med Hypotheses; 2010 Dec; 75(6):544-6. PubMed ID: 20708340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder.
    Riggs PD; Leon SL; Mikulich SK; Pottle LC
    J Am Acad Child Adolesc Psychiatry; 1998 Dec; 37(12):1271-8. PubMed ID: 9847499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of ADHD and its treatment on substance abuse in adults.
    Wilens TE
    J Clin Psychiatry; 2004; 65 Suppl 3():38-45. PubMed ID: 15046534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychiatry; 2006; 67 Suppl 8():32-8. PubMed ID: 16961428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Selective noradrenaline-dopamine reuptake inhibition (SNDRI). More latitude for antidepressive therapy].
    MMW Fortschr Med; 2007 May; 149 Suppl 2():88-9. PubMed ID: 17724976
    [No Abstract]   [Full Text] [Related]  

  • 13. Bupropion in atopic dermatitis.
    González E; Sanguino RM; Franco MA
    Pharmacopsychiatry; 2006 Nov; 39(6):229. PubMed ID: 17124645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wellbutrin versus generic bupropion.
    Med Lett Drugs Ther; 2008 Jul; 50(1290):54-5. PubMed ID: 18617874
    [No Abstract]   [Full Text] [Related]  

  • 15. Psychopharmacology of smoking cessation in patients with mental illness.
    Selby P
    J Psychiatry Neurosci; 2006 Sep; 31(5):360. PubMed ID: 16951737
    [No Abstract]   [Full Text] [Related]  

  • 16. Khat and synthetic cathinones: a review.
    Valente MJ; Guedes de Pinho P; de Lourdes Bastos M; Carvalho F; Carvalho M
    Arch Toxicol; 2014 Jan; 88(1):15-45. PubMed ID: 24317389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder.
    Kunwar A; Dewan M; Faraone SV
    Expert Opin Pharmacother; 2007 Apr; 8(5):555-62. PubMed ID: 17376012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of a case of comorbid bipolar disorder and attention-deficit/hyperactivity disorder.
    Schaller JL; Behar D
    J Neuropsychiatry Clin Neurosci; 1998; 10(2):235-6. PubMed ID: 9608417
    [No Abstract]   [Full Text] [Related]  

  • 19. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
    Dhir A; Kulkarni SK
    Eur J Pharmacol; 2007 Jul; 568(1-3):177-85. PubMed ID: 17509558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-deficit hyperactivity disorder.
    Lee MS; Yang JW; Ko YH; Han C; Kim SH; Lee MS; Joe SH; Jung IK
    Child Psychiatry Hum Dev; 2008 Jun; 39(2):201-9. PubMed ID: 17763937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.